EGFR and cancer: Interestingly, when we include top molecular alterations at the proteomic level, possible alternate pathways are evident such as EGFR tyrosine kinase inhibitor resistance, proteoglycans in cancer, and other pathways in cancer providing opportunities to explore a multi-agent approach for this disease.